chufangao/CTO huggingface dataset:
Clinical trial NCT03630809: Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
Official title: Immune Response Surveillance and Potential Booster Vaccines for Patients Who Have Received HER2-pulsed DC1 Vaccine
Sponsor: H. Lee Moffitt Cancer Center and Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Quality of the data originating from prior versions of the protocol has been affected by protocol deviations triggered by the COVID-19 pandemics
Enrollment: 16.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-01-10
Primary completion date: 2022-04-11
Completion date: 2022-04-11
Clinical trial NCT01988831: Efficacy of Propranolol Treatment to Prevent Melanoma Progression
Official title: Phase 2 Prospective Study of the Efficacy of Propranolol on Malignant Melanoma Progression. A Randomized Placebo-controlled,Single Blind Trial
Sponsor: University Hospital, Geneva (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: We must delay the study for some financial reasons
Enrollment: 450.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2016-06-30
Primary completion date: 2022-01-31
Completion date: 2022-03-31
Clinical trial NCT04405180: Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age
Official title: Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age
Acronym: Nitrite
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 64.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-23
Primary completion date: 2023-07-14
Completion date: 2023-07-14
Limitations and caveats: Departures from the muscle preservation protocol resulted in widespread ice artifact in the majority of mounted tissue samples. Nearly all muscle samples are non-viable for histological and morphological analyses. Consequently, skeletal muscle histological and morphological outcomes (cross sectional area, fiber type, fiber type area, and mitochondrial content) were omitted due to to technical limitations and predominant doubts regarding the reliability of the data.
Plan to share individual participant data: YES
IPD sharing description: De-Identified data may be shared with other future investigators as research questions arise.
IPD time frame: A limit in time frame of sharing has not been defined.
IPD access criteria: Only de-identified data approved for sharing by PI.
Clinical trial NCT05295927: A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Official title: A Phase 1b Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone or Apalutamide in mCRPC (ARES: Androgen Receptor Eradication Study)
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Administrative Decision
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-23
Primary completion date: 2022-09-30
Completion date: 2022-09-30
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT05240560: Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke
Official title: A Multisite Randomized Clinical Trial Evaluating Efficacy and Safety of BP1.3656 vs Placebo in Patients With Fatigue Following Ischemic Stroke
Sponsor: Bioprojet (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of recruitment
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-01-20
Primary completion date: 2024-02-08
Completion date: 2024-02-08
Plan to share individual participant data: NO
Clinical trial NCT04279561: Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
Official title: Effects of Novel Androgen Receptor Signaling Inhibitors on PSMA PET Signal Intensity in Patients With Castrate-Resistant Prostate Cancer: A Prospective Exploratory Study
Sponsor: Jonsson Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: slow accrual
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-16
Primary completion date: 2022-09-15
Completion date: 2022-09-15
Clinical trial NCT04390594: Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal
Official title: Multicentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in Senegal
Acronym: SEN-CoV-Fadj
Sponsor: Institut Pasteur de Dakar (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: In conclusion, the results of the SEN-CoV Fadj trial to date do not meet the objectives of the clinical trial and the sample size required to meet them is clearly too large to be achieved within a reasonable time.
Enrollment: 59.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-13
Primary completion date: 2023-02-08
Completion date: 2023-02-08
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05474690: A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
Official title: A Non-inferior, Randomized Controlled Phase III Clinical Study Comparing the Efficacy of TCbHPand ECHP-THP in Neoadjuvant Treatment of Operable HER2-positive Breast Cancer
Sponsor: Henan Cancer Hospital (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The new treatment plan for HER2 positive breast cancer has entered the diagnosis and treatment guide. The treatment plan ECHP-THP in this study is not the optimal treatment plan, therefore this study was terminated.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-11
Primary completion date: 2023-03-28
Completion date: 2024-08-30
Clinical trial NCT03803254: HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
Official title: Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Programmed Cell Death Protein-1 Antibody Versus Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Advanced Hepatocellular Carcinoma
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-03
Primary completion date: 2021-01-01
Completion date: 2021-01-01
Clinical trial NCT03165721: A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
Official title: A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study closed to enrollment due to low accrual.
Enrollment: 9.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-08-16
Primary completion date: 2020-02-24
Completion date: 2020-02-24
Plan to share individual participant data: NO
Clinical trial NCT04684550: Use of Hypochlorous Acid as Prophylaxis in Health Personnel at High Risk of Infection by SARS-CoV 2 (COVID19)
Official title: Randomized Controlled Clinical Study (RCT) Phase 3 of the Safety and Efficacy of Hypochlorous Acid in the Prophylaxis of Healthcare Personnel at High Risk of Infection by SARS-CoV2 (COVID19) Versus Placebo
Sponsor: Hospital Universitario San Ignacio (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: The study did not achieve funding or approval by the ethics committee. Once the vaccination phase was entered, the study lost validity and was not viable
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-15
Primary completion date: 2021-06-15
Completion date: 2021-08-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02939742: Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?
Official title: Does a Repeat Course of Antenatal Corticosteroids in Pregnant Women With Preterm Premature Rupture of Membranes Decrease Neonatal Morbidity?
Sponsor: The University of Texas Medical Branch, Galveston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Low study recruitment
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-11-30
Primary completion date: 2023-12-20
Completion date: 2023-12-20
Plan to share individual participant data: NO
Clinical trial NCT02856581: Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes
Official title: Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Sponsor: Alliance for Clinical Trials in Oncology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 23.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-29
Primary completion date: 2021-05-28
Completion date: 2022-04-15
Clinical trial NCT04100096: A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder
Official title: A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 332.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-17
Primary completion date: 2021-06-27
Completion date: 2021-06-27
Baseline population: Randomized population included all participants who were randomized to receive brexpiprazole or matching placebo in the treatment phase.
Plan to share individual participant data: YES
IPD sharing description: Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
IPD time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
IPD access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Clinical trial NCT03259334: Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
Official title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Acronym: FIGARO UC 301
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.
Enrollment: 380.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-02-09
Primary completion date: 2020-07-22
Completion date: 2020-10-23
Baseline population: The safety set consisted of all participants who had received at least 1 dose of investigational product.
Limitations and caveats: The study was terminated early as per the sponsor decision to discontinue the ontamalimab clinical trial development program for inflammatory bowel diseases (IBD) for reasons unrelated to safety and efficacy.
Clinical trial NCT03927248: PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
Official title: Pilot Study of Nivolumab and Procaspase Activating Compound-1 (PAC-1) for
Sponsor: HealthPartners Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: funding issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-30
Primary completion date: 2021-09-30
Completion date: 2021-12-31
Clinical trial NCT04357353: The Role of Platelet Rich Plasma for Erectile Dysfunction
Official title: The Role of Platelet Rich Plasma for Erectile Dysfunction
Sponsor: University of Nebraska (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: low enrollment
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-01
Primary completion date: 2022-11-02
Completion date: 2022-11-02
Plan to share individual participant data: NO
Clinical trial NCT05039710: A Study of JNJ-75220795 in Japanese Participants
Official title: A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795 in Japanese Participants
Sponsor: Janssen Pharmaceutical K.K. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business Judgement
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-08
Primary completion date: 2023-02-17
Completion date: 2023-02-22
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT01341652: Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer
Official title: Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) Versus GM-CSF Adjuvant in Patients With Non-Metastatic Prostate Cancer
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 99.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-05-23
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Baseline population: Baseline characteristics include those who completed the study.
Clinical trial NCT05118386: Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults
Official title: A Phase 1 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of RSM01, a Monoclonal Antibody Targeting Respiratory Syncytial Virus, in Healthy Adults
Sponsor: Bill & Melinda Gates Medical Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 56.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-16
Primary completion date: 2022-08-23
Completion date: 2022-12-07
Baseline population: Safety Population: included all participants who received the study treatment.
Plan to share individual participant data: YES
IPD sharing description: Anonymized or deidentified, as appropriate, participant level data may be shared with external researchers in accordance with the trial participants' written and executed informed consent document and any local or applicable regulations on data sharing. Qualified researchers may submit a request for anonymized or de-identified participant level data along with a research proposal to Gates MRI for review. A data sharing agreement must be in place before any clinical trial data are shared. There are additional circumstances that may prevent the sharing of data with external researchers, including but not limited to contractual obligations to existing partners and any restrictions imposed by regulatory bodies.
Clinical trial NCT04653818: HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial
Official title: Does Directly Acting Antivirals Usage Affect HCV Related Hepatocellular Carcinoma Recurrence After Percutaneous Ablation: A Randomized Controlled Trial
Acronym: RCT
Sponsor: Alexandria University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 84.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-05
Primary completion date: 2022-10-24
Completion date: 2022-10-24
Plan to share individual participant data: YES
Clinical trial NCT04824131: Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females
Official title: Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females - A Sub-study of HPTN 084
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 55.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-04
Primary completion date: 2023-01-10
Completion date: 2023-01-10
Baseline population: Includes all enrolled participants
Clinical trial NCT03060447: Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers
Official title: A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-09
Primary completion date: 2020-02-13
Completion date: 2020-02-13
Baseline population: The Safety Analysis Set included all participants who were randomized and received at least 1 dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT01679080: The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
Official title: The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
Sponsor: University of Aarhus (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Eli Lilly has withdrawn support to the study of teriparatide and placebo pens. The study was not able to continue as a randomized study without the supply of placebo pens.
Enrollment: 9.0 (ACTUAL)
Number of arms: 3.0
Start date: 2012-11-30
Primary completion date: 2020-07-01
Completion date: 2021-06-01
Clinical trial NCT02993224: Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet
Official title: Open-label, Multicenter, Single Arm, Phase II Study Assessing Treatment Patient Preference for New Deferasirox Formulation (Film-coated Tablet) Compared to the Reference Deferasirox Dispersible Tablet Formulation
Acronym: Jupiter
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 148.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-27
Primary completion date: 2020-01-29
Completion date: 2021-03-11
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT02380352: Short-course Antimicrobial Therapy for Paediatric Respiratory Infections
Official title: Short-course Antimicrobial Therapy for Paediatric Respiratory Infections
Acronym: SAFER
Sponsor: Hamilton Health Sciences Corporation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 281.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-09-30
Primary completion date: 2019-12-31
Completion date: 2020-04-30
Clinical trial NCT02654587: OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
Official title: A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Acronym: ATALANTE-1
Sponsor: OSE Immunotherapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: due to COVID-19
Enrollment: 219.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-02-12
Primary completion date: 2021-01-15
Completion date: 2021-01-15
Baseline population: 219 HLA-A2 positive patients with advanced NSCLC who progressed after sequential or concurrent chemotherapy and Immune Checkpoint Inhibitor (either primary or secondary resistance) were randomized. Safety analysis was done in overall population. Primary efficacy analysis was carried out from stratification factor in subgroup of patients with ICI secondary resistance (who had a disease progression after ICI second line \> or equal to 12 weeks)
Limitations and caveats: In April 2020 at time of planned interim analysis, decision was taken to prematurely stop the accrual due to COVID-19. Early termination led to small numbers of subject analyzed. The statistical plan was revised to propose the primary efficacy analysis in subgroup of patients with ICI secondary resistance (defined as progression after ICI second line \>= to 12 weeks from stratification criteria based on biological and clinical rationale).
Plan to share individual participant data: NO
IPD sharing description: The supporting information as Study Protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR) may be shared with other researchers if OSE Immunotherapeutics agreed and after signature of a confidential agreement between the parties
Clinical trial NCT03637803: Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
Official title: A Phase I/II Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors
Sponsor: 4D pharma plc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor insolvency
Enrollment: 63.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-10
Primary completion date: 2023-05-08
Completion date: 2023-05-08
Plan to share individual participant data: NO
Clinical trial NCT04875806: A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Official title: A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Sponsor: NextCure, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Due to the limited activity in Phase 1, NextCure decided to discontinue development of the anti-B7-H4 antibody monotherapy trial (NC762-01) to move forward with a prioritized B7-H4 ADC program.
Enrollment: 40.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-06-30
Primary completion date: 2024-01-30
Completion date: 2024-01-30
Plan to share individual participant data: NO